Month: May 2024

FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of...

NEEDHAM, Mass., May 6, 2024 /PRNewswire/ -- Tripadvisor, Inc. (NASDAQ: TRIP) announced today that the Company has updated the date...

COLUMBIA, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Tenable®, the Exposure Management company, today announced its chief financial officer, Steve...

OAKLAND, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- ThredUp Inc. (Nasdaq: TDUP, LTSE: TDUP), one of the largest online resale...

MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology...

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ: TBIO), a leading provider of RNA...

WILMINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the...

SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and...

BARTLETT, Tenn., May 06, 2024 (GLOBE NEWSWIRE) -- SurgePays, Inc. (Nasdaq: SURG) (“SurgePays” or the “Company”), a technology and telecommunications...

BARTLETT, Tenn., May 06, 2024 (GLOBE NEWSWIRE) -- SurgePays, Inc. (Nasdaq: SURG) (“SurgePays” or the “Company”), a technology and telecommunications...

SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for...

ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated...

TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:The sessions...

Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first...

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) -- Initiation of Phase...

Contacts Media & Investor Contact: Stacy Roughan Quince Therapeutics, Inc. Vice President, Corporate Communications & Investor Relations ir@quincetx.com Quince Therapeutics,...

Accelerated Turnaround of U.S. Business Continuing to Gain Momentum NORFOLK, Va., May 6, 2024 /PRNewswire/ -- PRA Group, Inc. (Nasdaq:...

EAGLE, Idaho, May 06, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant...

FAIRFAX, Va., May 6, 2024 /PRNewswire/ -- Playa Hotels & Resorts N.V. (the "Company" or "Playa") (NASDAQ: PLYA) today announced...

BEACON-IPF pivotal, adaptive Phase 2b/3 trial design implementation significantly accelerates bexotegrast development in IPFData from completed 12 week Phase 2a imaging...

Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or...

Total revenue per attendee up 26% year-over-year Upfront revenue up 16% and scatter revenue doubled year-over-year Contacts INVESTOR: Chan Park...

Contacts IR and PR Contact IR@serestherapeutics.com Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company,...

Contacts MEDIA CONTACT: Sophia Hong Lattice Semiconductor 503-268-8786 Sophia.Hong@latticesemi.com INVESTOR CONTACT: Rick Muscha Lattice Semiconductor 408-826-6000 Rick.Muscha@latticesemi.com Lattice Semiconductor (NASDAQ:...

Net revenue of $366.5 million GAAP gross margin of 16.2%; Non-GAAP gross margin of 32.6% GAAP operating loss of 31.3%;...

Contacts Megan E. Knight VP, Head of Investor Relations IR@longboardpharma.com 858.789.9283 Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company...

MIDDLETOWN, R.I., May 06, 2024 (GLOBE NEWSWIRE) -- KVH Industries, Inc. (Nasdaq: KVHI) reported financial results for the quarter ended...

Contacts Investors: Greg Martini, 617-374-5230 gmartini@ironwoodpharma.com Matt Roache, 617-621-8395 mroache@ironwoodpharma.com Media: Beth Calitri, 978-417-2031 bcalitri@ironwoodpharma.com Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD)...

Quarterly Revenue of $265 Million, 11% Year Over Year Growth Maintains Strong Profitability with Diluted EPS of $0.67 Declares $0.15...

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- FTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems,...

SAN FRANCISCO, May 06, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter...

Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of...

Contacts For further information about this topic please contact: Richard Catalano, Executive Vice President & CFO Phone: (631) 981-7081 Email:...

Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024Soquelitinib Registration...

Contacts Investor Relations: Dean Ridlon Cognyte Software Ltd. IR@cognyte.com Cognyte Software Ltd. (NASDAQ: CGNT) (“Cognyte”), a global leader in investigative...

New York, May 6, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies...

New York, May 6, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies...